Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Name:	us-gaap_Assets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Segment Reporting (Details Narrative) $ in Thousands	3 Months Ended	9 Months Ended
Segment Reporting (Details Narrative) $ in Thousands	Sep. 30, 2018 USD ($)	Sep. 30, 2018 USD ($) Products	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Number of operating segments \| Products		1
Number of reportable segments \| Products		2
Total assets	$ 9,404	$ 9,404		$ 4,983
Sale of preferred stock, cash value		3,000
Series A Preferred Stock [Member]
Sale of preferred stock, cash value	3,000
Renal Products Segment [Member]
Total assets	$ 3,000	$ 3,000